
VIVO Earnings & Financial Statements
Meridian Bioscience, Inc.
$1.82
-$0.05(-2.67%)
22
Overall
--
Value
10
Tech
34
Quality
Market Cap
$57.45M
Volume
452.89K
52W Range
$1.20 - $6.86
Target Price
$10.00
VIVO earnings and financial statements: Meridian Bioscience, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
VIVO Annual Financial Statements
| Fiscal year | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | $2.54M | $61.0K | $16.0K | $4.05M | $20.57M |
| Cost of revenue | $1.93M | $50.0K | $27.0K | $8.14M | -$20.31M |
| Operating income | -$26.61M | -$11.61M | -$8.66M | -$11.74M | -$23.29M |
| EBITDA | -$40.16M | -$8.80M | -$36.68M | -$11.09M | -$20.97M |
| Net income | -$49.73M | -$17.04M | -$43.55M | -$24.36M | -$42.09M |
| EPS (diluted) | $-2.59 | $-2.60 | $-15.17 | $-9.87 | $-1.04 |
| Fiscal year | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Total assets | $156.43M | $92.74M | $37.43M | $61.42M | $69.66M |
| Total liabilities | $119.49M | $75.50M | $77.97M | $57.67M | $47.69M |
| Shareholders’ equity | $36.93M | $17.24M | -$40.54M | $3.75M | $21.97M |
| Cash and equivalents | $2.02M | $60.0K | $199.0K | $553.0K | $1.28M |
| Long-term debt | $25.41M | $16.94M | $20.91M | $30.00M | $23.45M |
| Fiscal year | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Operating cash flow | -$3.59M | -$7.71M | $1.49M | -$5.44M | -$5.13M |
| Capital expenditure | - | - | - | - | -$1.11M |
| Free cash flow | -$4.41M | -$7.84M | $884.0K | -$6.36M | -$6.24M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | VIVO | $1.82 | -2.7% | 452.89K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Meridian Bioscience, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW